The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis

Archives of Internal Medicine

Volumn 169, Issue 12, 2009, Pages 1104-1112

  Clement, Fiona M ^a   Klarenbach, Scott ^b   Tonelli, Marcello ^b   Johnson, Jeffrey A ^c   Manns, Braden J ^a,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Institute for Health Economics   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MENTAL HEALTH; META ANALYSIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; REVIEW; SHORT FORM 36; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VALIDATION STUDY;

ANEMIA; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 67649476202     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.112     Document Type: Review

References (29)

1. Barrett BJ, Fenton SS, Ferguson B, et al; Canadian Society of Nephrology. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol. 1999; 10(suppl 13):S292-S296.
2. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5)(suppl 3):S11-S145.
3. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
4. US Food and Drug Administration. Procrit label, Epogen label. 2007. http://www.fda.gov/cder/foi/label/2007/103234s5122lbl.pdf. Accessed August 14, 2008.
5. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530. (Pubitemid 47285453)
6. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
7. Bahlmann J, Schoter KH, Scigalla P, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol. 1991;88:90-106.
8. Furuland H, Linde T, Ahlmén J, Christensson AJ, Strömbom A, Danielson U. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18(2):353-361. (Pubitemid 36181688)
9. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66(2):753-760. (Pubitemid 38982019)
10. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25(4):548-554.
11. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47(5):738-750.
12. Ongoing safety review erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen) [and] darbepoetin alfa (marketed as Aranesp): update. US Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/ RHE/default.htm. Accessed August 7, 2008.
13. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590. (Pubitemid 28385655)
14. Eknoyan G, Beck GJ, Cheung AK, et al; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010-2019.
15. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-1137. (Pubitemid 47609037)
16. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415. (Pubitemid 20025670)
17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
19. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1538-1558. (Pubitemid 34746062)
20. Wyrwich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD; Heart Disease Expert Panel. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147(4):615-622. (Pubitemid 38900445)
21. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40(2):577-591. (Pubitemid 40470709)
22. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300(6724):573-578. (Pubitemid 20090272)
23. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58(3):1325-1335. (Pubitemid 30678057)
24. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46(5):799-811. (Pubitemid 41505453)
25. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16(7):2180-2189. (Pubitemid 41716451)
26. Ritz E, Laville M, Bilous RW, et al; Anemia Correction in Diabetes Study Investigators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49(2):194-207.
27. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15(1):148-156. (Pubitemid 38020706)
28. Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making. 2005;25(3):250-261. (Pubitemid 40696275)
29. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005;46(3):481-488. (Pubitemid 41208184)